Ascendis Pharma, Inc.

Ascendis Pharma, Inc. is a foreign-owned, for-profit pharmaceutical company registered in SAM.gov since January 11, 2019, with its registration set to expire on February 28, 2025. The company specializes in developing and providing pharmaceutical products, primarily focused on rare disease treatments. Through its federal contract awards, Ascendis Pharma, Inc. supplies specialized pharmaceutical products to the U.S. Department of Veterans Affairs (VA), with a particular emphasis on drugs that address complex medical conditions such as short bowel syndrome.

The company has been awarded multiple federal contract awards specifically focused on delivering pharmaceutical products to veterans' healthcare facilities. Its primary federal contract awards include delivery of drugs like YORVIPATH 168MCG INJ,SOLN,PEN and Skytrofa, which are used to treat specific medical conditions. These contracts are not set aside and have been awarded directly by the VA's Veterans Integrated Service Network and National Acquisition Center. The contract values range from $25,000 for interim agreements to $210,087.80 for specific delivery orders, demonstrating the company's ability to provide targeted pharmaceutical solutions to federal healthcare systems.

Ascendis Pharma, Inc. holds several significant Federal Contract Indefinite Delivery Vehicles (IDVs), including a $59.8 million multiple-award Federal Supply Schedule contract under the Pharmaceuticals and Drugs (FSS-61-IB) schedule, valid through July 14, 2027. The company also maintains a $7.3 million single-award Blanket Purchase Agreement with the VA National Acquisition Center. These IDVs enable the VA to procure critical pharmaceuticals and medical products through streamlined task order mechanisms. The contract vehicles cover drugs, pharmaceuticals, and hematology-related products, specifically supporting healthcare services for U.S. veterans and addressing specialized medical treatment needs.